Federation Bio


Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company’s microbial approach leverages naturally occurring bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a diverse set of human conditions ranging from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions. Federation Bio’s lead program is in secondary hyperoxaluria, a serious renal condition that affects more than 200,000 Americans and for which there are currently no approved therapies. Additional information can be found at www.federation.bio

Company Information

April 20, 2022